Influence of recombinant human prourokinase combined tirofiban on cardiac function and prognosis in ASTEMI patients undergoing PCI
10.3969/j.issn.1008-0074.2024.04.17
- VernacularTitle:重组人尿激酶原联合替罗非班对经PCI治疗ASTEMI患者心功能及预后的影响
- Author:
Han-Shuo JIA
1
;
Tao JIANG
;
De-Liang WANG
;
Jian-Xing PEI
Author Information
1. 保定市第二中心医院心内科,河北保定 072750
- Keywords:
Myocardial infarction;
Angioplasty,balloon,coronary;
Prognosis;
Tirofiban
- From:
Chinese Journal of cardiovascular Rehabilitation Medicine
2024;33(4):461-465
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the effect of recombinant human prourokinase combined with tirofiban on cardiac func-tion and prognosis in patients with acute ST-segment elevation myocardial infarction(ASTEMI)undergoing emergency percutaneous coronary intervention(PCI).Methods:A total of 156 ASTEMI patients undergoing PCI treated in our hos-pital from June 2019 to December 2020 were selected.They were equally divided into control group(received tirofiban in-jection during emergency PCI)and study group(received recombinant human prourokinase injection based on control group)according to random number table method.Two groups received the same medication before and after emergency PCI.Thrombolysis in myocardial infarction(TIMI)flow,TIMI myocardial perfusion grade(TMPG)before and after PCI,cardiac function indexes before and one week after PCI,incidence of major adverse cardiovascular events(MACE)and adverse reactions within 1-year follow-up were compared between two groups.Results:After PCI,compared with control group,there were significant rise in proportions of TIMI flow grade 3(51.28％vs.83.00％)and TMPG grade 3(51.28％vs.84.62％),left ventricular ejection fraction(LVEF)one week after PCI[(44.26±3.45)％vs.(49.17±2.92)％],and significant reductions in left ventricular end-diastolic diameter(LVEDd)[(56.47±2.54)mm vs.(51.32±2.55)mm],left ventricular end-systolic diameter(LVESd)[(41.86±2.49)mm vs.(36.01±1.68)mm]one week after PCI,incidence rates of MACE(24.36％vs.7.69％)and adverse reactions(10.26％vs.1.28％)within 1-year fol-low-up in study group(P＜0.05 or＜0.01).Conclusion:Recombinant human prourokinase combined with tirofiban can significantly improve cardiac function,reduce the incidence rates of MACE and adverse reactions,and improve the prog-nosis in ASTEMI patients after PCI,which is worthy of clinical reference.
